Article Text
Correspondence response
Response to: ‘Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?’ by Cantini and Benucci
Statistics from Altmetric.com
In their correspondence, Cantini and Benucci1 express their concern about the lack of real-life data supporting the switch from originator to biosimilar biological disease-modifying antirheumatic drugs, as recommended in the recently issued consensus-based recommendations.2 They argue that the Danish Nationwide Biologic (DANBIO) registry reporting real-life data showed a lower than expected retention rate after the switch to biosimilar infliximab (bio-IFX) and etanercept.3 4
Concerning bio-IFX, several other real-life studies have been published so far. One Dutch and one French open studies have examined real-life outcomes of the switch from originator to bio-IFX in patients with inflammatory rheumatic diseases.5 6 Both …